Telix Pharmaceuticals (TLPPF) reported third-quarter revenue growth of 53% year-over-year and raised its fiscal year 2025 revenue guidance to $800-820 million. The company plans to increase research and development investment to support its expanding clinical pipeline, demonstrating its commitment to innovation in the pharmaceutical sector.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.